[go: up one dir, main page]

MX2017013788A - Composicion farmaceutica estabilizada. - Google Patents

Composicion farmaceutica estabilizada.

Info

Publication number
MX2017013788A
MX2017013788A MX2017013788A MX2017013788A MX2017013788A MX 2017013788 A MX2017013788 A MX 2017013788A MX 2017013788 A MX2017013788 A MX 2017013788A MX 2017013788 A MX2017013788 A MX 2017013788A MX 2017013788 A MX2017013788 A MX 2017013788A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
stabilized
stabilized pharmaceutical
compound
pharmaceutically acceptable
Prior art date
Application number
MX2017013788A
Other languages
English (en)
Inventor
Yoshida Mitsuru
Tasaki Hiroaki
Tsunashima Daisuke
Azuma Ryota
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2017013788A publication Critical patent/MX2017013788A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente invención se proporciona una composición farmacéutica que comprende 5-{[(3R)-1-acriloilpirrolidin-3-il]oxi} -6-etil-3-({4-[4-(4-metilpiperazin-1-il)piperidin-1-il]fenil}amin o)-pirazina-2-carboxamida (aquí denominada "compuesto A") o una sal farmacéuticamente aceptable del mismo y se estabiliza. La composición farmacéutica comprende el compuesto A o una sal farmacéuticamente aceptable del mismo y un aditivo farmacéutico que tiene una diferencia en el valor de la actividad del agua de 0.1 o más y se estabiliza.
MX2017013788A 2015-04-27 2016-04-26 Composicion farmaceutica estabilizada. MX2017013788A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015090702 2015-04-27
JP2015252958 2015-12-25
PCT/JP2016/063004 WO2016175192A1 (ja) 2015-04-27 2016-04-26 安定化されてなる医薬組成物

Publications (1)

Publication Number Publication Date
MX2017013788A true MX2017013788A (es) 2018-03-27

Family

ID=57198490

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013788A MX2017013788A (es) 2015-04-27 2016-04-26 Composicion farmaceutica estabilizada.

Country Status (12)

Country Link
US (1) US10188737B2 (es)
EP (1) EP3290036A4 (es)
JP (2) JP6112530B2 (es)
KR (1) KR20170139154A (es)
CN (1) CN108135898A (es)
CA (1) CA2983400A1 (es)
HK (1) HK1250491A1 (es)
MX (1) MX2017013788A (es)
PH (1) PH12017501832A1 (es)
RU (1) RU2017140923A (es)
TW (1) TWI689306B (es)
WO (1) WO2016175192A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201827052A (zh) * 2016-10-26 2018-08-01 日商安斯泰來製藥股份有限公司 安定的醫藥組成物
KR102406067B1 (ko) 2017-10-25 2022-06-08 현대자동차주식회사 가변형 에어벤트
WO2023129667A1 (en) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006045218A (ja) 2004-07-08 2006-02-16 Ono Pharmaceut Co Ltd 経口投与用医薬組成物
CN104080774B (zh) * 2012-01-17 2017-02-22 安斯泰来制药株式会社 吡嗪甲酰胺化合物
JP6084371B2 (ja) 2012-05-23 2017-02-22 富士製薬工業株式会社 薬剤安定化医薬組成物
JPWO2015182628A1 (ja) 2014-05-28 2017-04-20 アステラス製薬株式会社 ピラジンカルボキサミド化合物を有効成分とする医薬組成物

Also Published As

Publication number Publication date
KR20170139154A (ko) 2017-12-18
CA2983400A1 (en) 2016-11-03
TW201703772A (zh) 2017-02-01
WO2016175192A1 (ja) 2016-11-03
TWI689306B (zh) 2020-04-01
RU2017140923A (ru) 2019-05-27
CN108135898A (zh) 2018-06-08
PH12017501832A1 (en) 2018-04-23
JP6112530B2 (ja) 2017-04-12
EP3290036A1 (en) 2018-03-07
EP3290036A4 (en) 2019-01-02
US10188737B2 (en) 2019-01-29
JP2017119703A (ja) 2017-07-06
JPWO2016175192A1 (ja) 2017-05-18
HK1250491A1 (zh) 2018-12-21
US20180133325A1 (en) 2018-05-17

Similar Documents

Publication Publication Date Title
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
PH12019500395A1 (en) Amino-pyrrolopyrimidinone compounds and methods of use thereof
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
EA033689B9 (ru) Ингибиторы g12c kras
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
EA201991884A3 (ru) Ингибиторы g12c kras
GEP20186892B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
NZ716487A (en) Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
MX2019000536A (es) Nuevas pirimidinas carboxamidas como inhibidores de enzima vanina-1.
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
MX2013005020A (es) Composiciones y metodos para el tratamiento de la mielofibrosis.
MX2021002261A (es) Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
PH12018500378A1 (en) Novel annelated phenoxyacetamides
PH12017501397B1 (en) (2s, 4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor
MY197595A (en) Alkyl dihydroquinoline sulfonamide compounds
PH12017502252B1 (en) Stable pharmaceutical composition for oral administration
PH12017501832A1 (en) Stabilized pharmaceutical composition
PH12017501444A1 (en) (2r,4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
WO2016165205A8 (zh) 一种新型的bcr-abl激酶抑制剂
TN2013000195A1 (en) Compositions and methods for treating myelofibrosis